CIK 0001782223 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831160910
- Phone
- (617) 221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- Open-market buys, last 90 days
- $0
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 4 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-21 | HUMPHREY RACHEL Director | Sale 10b5-1 | −13,896 | $1.03 | $14K | 81,309 |
| 2025-04-17 | HUMPHREY RACHEL Director | Sale 10b5-1 | −200 | $0.97 | $194 | 95,205 |
| 2025-04-14 | HUMPHREY RACHEL Director | Sale 10b5-1 | −1,400 | $0.97 | $1K | 95,405 |
| 2025-03-31 | Sullivan Lara President ,CEO & CMO | Grant or award · Stock Option (Right to Buy) | +918,308 | $0.98 | $900K | 918,308 |
| 2025-03-31 | Metzger Michael A Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Wadhane Jitendra SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +263,782 | $0.98 | $259K | 263,782 |
| 2025-03-31 | HUMPHREY RACHEL Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Lewis-Hall Freda C Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Cline Darren S Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Dupont Jakob Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Palani Santhosh Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Civik Thomas Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2025-03-31 | Connealy Pamela Ann CFO & COO | Grant or award · Stock Option (Right to Buy) | +414,163 | $0.98 | $406K | 414,163 |
| 2025-03-31 | FLAVIN JOHN L Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2024-12-23 | Sullivan Lara Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,135,000 | 1,135,000 | ||
| 2024-12-23 | Connealy Pamela Ann CFO & COO | Grant or award · Stock Option (Right to Buy) | +310,000 | 310,000 | ||
| 2024-12-23 | Wadhane Jitendra SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2024-11-26 | Connealy Pamela Ann CFO & COO | Purchase | +5,450 | $2.00 | $11K | 1,115,743 |
| 2024-11-26 | Connealy Pamela Ann CFO & COO | Purchase | +83,400 | $1.96 | $163K | 1,199,143 |
| 2024-06-10 | Metzger Michael A Director | Grant or award · Stock Option (Right to Buy) | +70,683 | 70,683 |
Page 2 of 7 · 137 trades